ham's Institutional Review Board approved this study and waived the need for informed consent for this database study. All investigations were conducted in conformity with ethical principles of research. We assessed the association of gout with uveitis using multivariable-adjusted Cox proportional hazards regression analyses, controlling for several covariates or potential confounders: age; race/ethnicity; sex comorbidities, assessed using the Charlson Comorbidity Index (Romano adaptation), a validated, weighted comorbidity measure; and use of cardiovascular medications (statins, β-blockers, diuretics, and angiotensin-converting enzyme inhibitors; data from Medicare Part D) and urate-lowering medications for gout (allopurinol and febuxostat). ; the respective incidence rates were 179 and 93 per 100 000 person-years. The mean (SD) time from gout diagnosis to the new diagnosis of uveitis was 804 (572) days (median, 694 days; interquartile range, 329-1190 days). Compared with individuals without incident uveitis, those with uveitis were significantly more likely to be older, female, and black and have more medical comorbidities ( Table 1) . After multivariable adjustment, gout was associated with 1.53-fold higher hazard of uveitis (95% CI, 1.39-1.69; P < .001) ( Table 2) , as were older age, female sex, black or other race/ethnicity, and comorbidities, including diabetes, chronic obstructive pulmonary disease, connective tissue disease, or any tumor, leukemia, or lymphoma (Table 2 ). Sensitivity analysis that replaced the continuous Charlson Comorbidity Index with a categorized scale or individual comorbidities confirmed the findings from the main analyses with minimal attenuation of hazard ratios (Table 2) .
Discussion | Gout was independently associated with a 1.5-fold higher risk of uveitis in the older individuals after adjustment for demographics, comorbidities, and medications, and the risk could be 1.4-to 1.9-fold higher. Proinflammatory cytokines, including tumor necrosis factor α and interleukins 1 and 6, are induced by exposure to monosodium urate crystals and released by monocytes in individuals with gout; elevated intraocular levels of these proinflammatory cytokines and systemic levels of C-reactive protein (inflammatory marker) are also seen in patients with uveitis. 6 Inflammation might explain the association and the increased risk of uveitis in individuals with gout, a hypothesis that should be tested. Hyperuricemia, oxidative stress, and other disease processes may also contribute to this association. A confirmation of this study finding and temporal association studies are needed for greater confidence in this finding, which is at risk of residual confounding bias or could be attributable to chance. We were unable to assess the effect of gout duration on the observed association, which needs further exploration. A clinically relevant implication of our finding is whether reduction of chronic inflammation in gout can reduce or eliminate this increased risk of uveitis in older adults. 
OBSERVATION

Association of Uveitis and Macular Edema With Anastrozole Therapy
Anastrozole is a nonsteroidal aromatase inhibitor (AI) commonly used as adjuvant therapy for postsurgical treatment of estrogen receptor-positive breast cancer. Although ocular adverse effects of tamoxifen (a selective estrogen receptor modulator) are well described, only a few studies [1] [2] [3] [4] have identified retinal hemorrhages, optic disk swelling, vitreoretinal traction, and dry eye as ocular adverse effects of AIs. This case report describes a patient with documented uveitis and cystoid macular edema (CME) during AI treatment.
Report of a Case | A 65-year-old woman with a history of breast carcinoma was referred to the retina clinic for CME in her right eye. Ocular history was remarkable for 3 recurrent episodes of bilateral iritis occurring during 5 months that were treated with prednisolone acetate drops, amblyopia in the left eye, and bilateral posterior chamber intraocular lens. She reported having several months of blurry vision in the right eye but denied any other symptoms.
The patient was diagnosed with left-sided, invasive lobular carcinoma, positive for estrogen and progesterone receptors and negative for ERBB2 (formerly HER2/neu), 2.5 years before presentation. She underwent left-sided mastectomy 2 months after diagnosis and initiated anastrozole therapy, which has continued for more than 2 years. Medical history and past medication use were unremarkable.
At presentation, Snellen visual acuity was 20/25 OD and 20/150 OS without improvement on pinhole testing. Intraocular pressures were normal. Anterior segment examination in the right eye was remarkable for trace conjunctival injection with no definite ciliary flush, 2+ fine keratic precipitates, and 1+ cells in the anterior chamber. A few keratic precipitates were noted on anterior segment examination in the left eye. Dilated fundus examination was notable for cystoid macular edema with a yellow spot in the fovea in the right eye and an epiretinal membrane in the left eye. No inflammation in the periphery was noted in either eye.
Optical coherence tomography ( Figure 1A ) confirmed findings of CME with an elevation of the outer retina beneath the fovea, trace epiretinal membrane in the right eye, and an epiretinal membrane in the left eye. Fluorescein angiography (Figure 2 ) showed bilateral CME with more leakage in the right eye.
Results of a systemic workup, including blood tests for vasculitis and rheumatologic disorders, were within reference limits. Suspicion of infectious diseases was low given the normal findings for tick-borne and bacterial diseases. Computed tomography of the chest was unremarkable for sarcoidosis.
Therapy consisting of difluprednate ophthalmic emulsion drops, 0.05%, 6 times daily for 3 days followed by 4 times daily for 1 month, was started in the right eye. Follow-up examination 1 month later revealed resolved iritis and resolution of CME on ocular coherence tomography ( Figure 1B) . The patient continues anastrozole therapy with near-complete resolution of symptoms.
Discussion | Given the absence of other systemic inflammatory processes and other drugs known to cause uveitis and macular edema, the patient's ocular presentation may have been caused by anastrozole. Some patients with idiopathic uveitis may respond to a course of topical corticosteroid drops, and this cannot be ruled out. Macular edema was previously reported in a 72-year-old patient receiving letrozole, 5 another AI, for 3 years, but review of the photographs show a pigment epithelial detachment that resolved with ranibizumab, so the patient may have had exudative age-related macular degeneration. Some authors theorized that depriving the retina of estrogen's neuroprotective effects leads to breakdown of the blood-retinal barrier. 5 This breakdown, implicated in diabetic retinopathy, age-related macular degeneration, and uveitis, often results in macular edema. Moschos et al 6 also demonstrated a decrease in retinal nerve fiber layer thickness using ocular coherence tomography in patients taking AIs in comparison with control
